GeneHealth - Your precision medicine

Thrombotic Thrombocytopenic Purpura

Disease Details

Family Health Simplified

Buy Membership

Description: Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clot formation in small blood vessels, leading to low platelet counts, hemolytic anemia, and potential organ damage.
Type: Thrombotic Thrombocytopenic Purpura (TTP) can be of two types:

1. **Acquired TTP**: This is not inherited but occurs due to the development of autoantibodies against the ADAMTS13 enzyme.
2. **Hereditary (or congenital) TTP**: This type is inherited in an autosomal recessive manner, due to mutations in the ADAMTS13 gene.
Signs And Symptoms: The signs and symptoms of TTP may at first be subtle and nonspecific. Many people experience an influenza-like or diarrheal illness before developing TTP. Neurological symptoms are very common and vary greatly in severity. Frequently reported symptoms include feeling very tired, confusion, and headaches. Seizures and symptoms similar to those of a stroke can also be seen. Other symptoms include, but are not limited to jaundice or paleness of the skin, a fast heart rate or shortness of breath, or dots on the skin known as petechiae. High blood pressure has also been observed as a symptom.As TTP progresses, blood clots form within small blood vessels (microvasculature), and platelets (clotting cells) are consumed. As a result, bruising, and rarely bleeding can occur. The bruising often takes the form of purpura, while the most common site of bleeding, if it occurs, is from the nose or gums. Larger bruises (ecchymoses) may also develop. The classic presentation of TTP, which occurs in less than 10% of people, includes five medical signs. These are:
Fever
Changes in mental status
Thrombocytopenia
Reduced kidney function
Hemolytic anemia (microangiopathic hemolytic anemia).
Prognosis: The mortality rate is around 95% for untreated cases, but the prognosis is reasonably favorable (80–90% survival) for people with idiopathic TTP diagnosed and treated early with plasmapheresis.
Onset: Thrombotic Thrombocytopenic Purpura (TTP) often has an abrupt onset. Symptoms can rapidly develop over days to weeks. Manifestations include fever, neurological symptoms (such as confusion or seizures), renal dysfunction, and purpura (bruising). Prompt recognition and treatment are critical due to the potential for severe complications.
Prevalence: Thrombotic thrombocytopenic purpura (TTP) is a rare condition with an estimated prevalence of approximately 4-6 cases per million people per year.
Epidemiology: The incidence of TTP is about 4–5 cases per million people per year. Idiopathic TTP occurs more often in women as well as people of African descent, and TTP secondary to autoimmune disorders such as systemic lupus erythematosus occurs more frequently in people of African descent, although other secondary forms do not show this distribution. Although Black people are at an increased risk for TTP, its presentation in Black people does not have any distinguishable features compared to those of other races. Pregnant women and women in the post partum period accounted for a notable portion (12–31%) of the cases in some studies; TTP affects about one in 25,000 pregnancies.
Intractability: Thrombotic Thrombocytopenic Purpura (TTP) is not necessarily intractable, but it can be life-threatening if not treated promptly. It is a rare blood disorder characterized by the formation of small blood clots that can block blood flow to vital organs. Treatment typically involves plasma exchange (plasmapheresis), corticosteroids, and sometimes immunosuppressive medications. Early diagnosis and immediate treatment are crucial for a favorable outcome.
Disease Severity: The severity of thrombotic thrombocytopenic purpura (TTP) can vary, but it is generally considered a medical emergency. Without prompt treatment, it can be life-threatening. TTP is characterized by the formation of small blood clots throughout the body, which can lead to complications such as organ damage, especially to the kidneys, heart, and brain. Early detection and treatment, often involving plasma exchange and immunosuppressive therapy, are crucial to improving outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:10772
Pathophysiology: The underlying mechanism typically involves autoantibody-mediated inhibition of the enzyme ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. The increase in circulating multimers of vWF increases platelet adhesion to areas of endothelial injury, particularly where arterioles and capillaries meet, which in turn results in the formation of small platelet clots called thrombi. As platelets are used up in the formation of thrombi, this then leads to a decrease in the number of overall circulating platelets, which may then cause life-threatening bleeds. Red blood cells passing the microscopic clots are subjected to shear stress, which damages their membranes, leading to rupture of red blood cells within blood vessels, which in turn leads to microangiopathic hemolytic anemia and schistocyte formation. The presence of the thrombi reduces blood flow to organs resulting in cellular injury and end organ damage.
Carrier Status: Thrombotic thrombocytopenic purpura (TTP) is not typically characterized by a carrier status because it is most often acquired rather than inherited. In acquired TTP, the condition is caused by autoantibodies that inhibit the ADAMTS13 enzyme. However, there is a hereditary form known as Upshaw-Schulman syndrome, which is due to inherited mutations in the ADAMTS13 gene. In this hereditary form, individuals may inherit one defective gene from each parent, making them carriers if they only have one defective gene but do not usually show symptoms.
Mechanism: Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clot formation in small blood vessels throughout the body, leading to low platelet counts, hemolytic anemia, and organ damage.

**Mechanism:**
1. **Formation of small blood clots (thrombi):** TTP involves the formation of microthrombi in the arterioles and capillaries.
2. **Reduced platelet count (thrombocytopenia):** The consumption of platelets in forming these clots leads to a low platelet count.
3. **Hemolytic anemia:** Red blood cells are sheared apart by the microthrombi, resulting in hemolytic anemia.
4. **Organ damage:** The microthrombi obstruct blood flow to various organs, causing ischemia and organ damage.

**Molecular Mechanisms:**
1. **ADAMTS13 deficiency:** The primary molecular mechanism involves a deficiency of the enzyme ADAMTS13, which normally cleaves von Willebrand factor (vWF) multimers. These multimers are involved in platelet adhesion and aggregation.
- **Inhibition:** In acquired TTP, autoantibodies inhibit ADAMTS13 activity.
- **Mutation:** In hereditary TTP (Upshaw-Schulman syndrome), mutations in the ADAMTS13 gene result in reduced or absent enzyme activity.
2. **Excessive vWF multimers:** The deficiency of ADAMTS13 leads to the accumulation of ultra-large vWF multimers that promote excessive platelet adhesion and aggregation, forming the microthrombi.
3. **Endothelial damage and inflammation:** The presence of these ultra-large vWF multimers can cause damage to the endothelial lining of blood vessels, contributing to the pathological process.

Overall, TTP's molecular basis lies in the impaired regulation of vWF due to an ADAMTS13 deficiency, leading to excessive platelet aggregation and microvascular thrombosis.
Treatment: Due to the high mortality of untreated TTP, a presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia are seen, and therapy is started. Transfusion is contraindicated in thrombotic TTP, as it fuels the coagulopathy. Since the early 1990s, plasmapheresis has become the treatment of choice for TTP. This is an exchange transfusion involving removal of the person's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure must be repeated daily to eliminate the inhibitor and abate the symptoms. If apheresis is not available, fresh frozen plasma can be infused, but the volume that can be given safely is limited due to the danger of fluid overload. Plasma infusion alone is not as beneficial as plasma exchange. Corticosteroids (prednisone or prednisolone) are usually given. Rituximab, a monoclonal antibody aimed at the CD20 molecule on B lymphocytes, may be used on diagnosis; this is thought to kill the B cells and thereby reduce the production of the inhibitor. A stronger recommendation for rituximab exists where TTP does not respond to corticosteroids and plasmapheresis.Caplacizumab is an alternative option in treating TTP as it has been shown that it induces a faster disease resolution compared with those people who were on placebo. However, the use of caplacizumab was associated with increase bleeding tendencies in some studied subjects.People with refractory or relapsing TTP may receive additional immunosuppressive therapy, e.g. vincristine, cyclophosphamide, cyclosporine A, or splenectomy.Children with Upshaw-Schulman syndrome receive prophylactic plasma every two to three weeks; this maintains adequate levels of functioning ADAMTS13. Some tolerate longer intervals between plasma infusions. Additional plasma infusions may be necessary for triggering events, such as surgery; alternatively, the platelet count may be monitored closely around these events with plasma being administered if the count drops.Measurements of blood levels of lactate dehydrogenase, platelets, and schistocytes are used to monitor disease progression or remission. ADAMTS13 activity and inhibitor levels may be measured during follow-up, but in those without symptoms the use of rituximab is not recommended.Apadamtase alfa (Adzynma) was approved for medical use in the United States in November 2023.
Compassionate Use Treatment: Thrombotic thrombocytopenic purpura (TTP) is a rare but serious disorder in which blood clots form in small blood vessels throughout the body. Compassionate use or access to experimental treatments may be considered for patients who fail conventional therapies. Here are some key approaches:

1. **Caplacizumab**: This is a targeted therapy that has shown promise in clinical trials. It inhibits the interaction between von Willebrand factor (vWF) and platelets, which is crucial in TTP.

2. **Rituximab**: Primarily used for lymphoma and autoimmune disorders, Rituximab is employed off-label in TTP to suppress the immune system's production of antibodies that inhibit ADAMTS13, a key enzyme involved in TTP.

3. **Recombinant ADAMTS13**: Experimental treatments focus on providing a synthetic version of the ADAMTS13 enzyme directly to patients, addressing the enzyme deficiency or inhibition that characterizes TTP.

4. **N-Acetylcysteine (NAC)**: Traditionally used for acetaminophen overdose, NAC is being studied for its potential to reduce vWF multimers, thereby counteracting one of the pathological processes in TTP.

These treatments are typically considered when standard therapies, such as plasma exchange and corticosteroids, are ineffective or contraindicated.
Lifestyle Recommendations: For thrombotic thrombocytopenic purpura (TTP), lifestyle recommendations often focus on managing overall health and preventing complications. These include:

1. **Medication Adherence**: Take prescribed medications consistently to manage the condition and prevent relapses.
2. **Regular Medical Checkups**: Frequent monitoring by healthcare providers is crucial for early detection and management of relapses or complications.
3. **Healthy Diet**: Consume a balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support overall health.
4. **Hydration**: Stay well-hydrated to help maintain good blood flow.
5. **Avoiding Infections**: Practice good hygiene and avoid exposure to people with infections, as infections can trigger TTP episodes.
6. **Stress Management**: Engage in stress-reducing activities like yoga, meditation, or hobbies to help maintain emotional well-being.
7. **Exercise**: Regular physical activity, as tolerated, to maintain cardiovascular health; however, avoid high-impact activities that could cause injury or excessive bleeding.
8. **Avoiding Certain Medications**: Consult with healthcare providers before taking any new medications, as some drugs (e.g., quinine, certain antibiotics) can exacerbate TTP.
9. **Monitoring Symptoms**: Stay vigilant for signs of relapse, such as unusual bruising, fatigue, or neurological symptoms, and seek immediate medical attention if they occur.

These recommendations aim to support overall well-being and reduce the risk of TTP flare-ups.
Medication: For thrombotic thrombocytopenic purpura (TTP), the primary treatment often involves plasma exchange (plasmapheresis) and corticosteroids. Rituximab, an immunosuppressive drug, may also be used in some cases. Other treatments can include immunosuppressive medications such as cyclosporine or vincristine. It's important for patients to work closely with a healthcare provider for individualized care.
Repurposable Drugs: Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clot formation in small blood vessels throughout the body. While treatment primarily involves plasma exchange and immunosuppressive therapy, some repurposable drugs include:

1. **Rituximab**: Originally used for non-Hodgkin's lymphoma and rheumatoid arthritis, rituximab has been effective in treating patients with TTP by targeting B-cells to reduce autoantibody production.
2. **Caplacizumab**: Developed for acquired TTP, it inhibits von Willebrand factor, helping to reduce clotting.
3. **N-acetylcysteine**: Known for its use in acetaminophen overdose, it has anticoagulant properties that may help in TTP.

These drugs show promise in treating TTP beyond their traditional uses.
Metabolites: In thrombotic thrombocytopenic purpura (TTP), the key metabolic abnormality involves a deficiency of the ADAMTS13 enzyme. This enzyme cleaves von Willebrand factor (vWF) multimers, and its deficiency or inhibition leads to the accumulation of large vWF multimers. These multimers contribute to platelet clumping, small blood vessel thrombosis, and the subsequent decrease in platelet count (thrombocytopenia). Other metabolic aspects are secondary to the organ damage caused by the microthromboses, such as hemolysis and ischemia-induced tissue injury. Specific metabolites related to these processes are not generally highlighted in standard diagnostic or treatment protocols for TTP.
Nutraceuticals: Nutraceuticals are food-derived products that provide health benefits beyond basic nutrition. However, there is insufficient clinical evidence to support the use of specific nutraceuticals for the treatment or management of thrombotic thrombocytopenic purpura (TTP). TTP is a rare blood disorder characterized by clot formation in small blood vessels, leading to low platelet counts, and requires prompt medical treatment such as plasma exchange and immunosuppressive therapy. Always consult healthcare professionals for appropriate treatment options.
Peptides: Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels, leading to a low platelet count. While peptides like ADAMTS13 play a crucial role in the understanding of TTP, nanoparticles are not a standard treatment or diagnostic tool for this condition as of now.

ADAMTS13 is an enzyme that cleaves von Willebrand factor (vWF), and a deficiency or inhibition of ADAMTS13 often leads to TTP. Treatments typically focus on plasma exchange and immunosuppressants to address the underlying causes. Research is ongoing, and the role of advanced materials in diagnosis and treatment of TTP may evolve.